ArticleCureus2025
Asymptomatic Cryptococcal Antigenemia: A Multi-clinic Cross-Sectional Study on the Prevalence, Associated Factors and Predictors of Three-Month Outcomes Among Antiretroviral-Naïve and Antiretroviral-Experienced HIV Patients in Dar es Salaam, Tanzania.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review of Risk Factors and Factors Influencing Outcomes of Cryptococcal Meningitis in Persons Living with HIV.Infection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCryptococcal meningitis remains a leading cause of HIV/AIDS-related mortality, predominantly in Sub-Saharan Africa. Current screening and prevention efforts primarily target antiretroviral therapy (ART)-naïve patients, whereas strategies for ART-experienced individuals are less well defined.
objectivesThis study primarily aimed at determining the prevalence of asymptomatic cryptococcal antigenemia (ACA) among ART-naïve and ART-experienced patients, along with associated factors and predictors of three-month outcomes among HIV patients in three HIV clinics in Dar es Salaam, Tanzania. Secondarily, factors associated with serum cryptococcal antigen positivity in the overall study population were also assessed.
methodsThis cross-sectional clinic-based study recruited 273 HIV-positive participants (ART-naïve and ART-experienced), attending three HIV care clinics in Dar es Salaam over a period of three months. A convenient sampling technique was employed, and all eligible participants were recruited until the desired sample size was reached. The study included adults (≥18 years) with recent CD4 cell counts of ≤200 cells/μL and ART-experienced patients (on ART treatment for more than six months) who had a viral load ≥1000 copies/mL. Individuals with symptoms of meningitis and recent fluconazole use were excluded. Screening for serum cryptococcal antigen (CrAg) was performed in all participants. The predetermined three-month outcomes, including development of meningitis, hospitalization, and mortality, were assessed.
resultsThe overall prevalence of ACA was 4.8% (13/273; 95% CI: 2.6-8.0). Among ART-experienced patients, the prevalence was 2.5% (4/162; 95% CI: 0.7-6.2), compared to 8.1% (9/111; 95% CI: 3.8-14.8) in the ART-naïve patients (p < 0.05). At three months, the likelihood of death, development of cryptococcal meningitis, or hospitalization was significantly higher among CrAg-positive patients (69%) compared to CrAg-negative patients (p < 0.05). Overall, a history of headache within the preceding two weeks and hospitalization in the past 12 months were significantly associated with CrAg positivity.
conclusionThe overall prevalence of ACA across the three HIV clinics in Dar es Salaam was 4.8%, with lower prevalence observed among ART-experienced patients compared to ART-naïve individuals. CrAg positivity was a strong predictor of adverse outcomes at three months in both populations. These findings underscore the need for more robust, risk-based guidelines on screening and surveillance even among ART-experienced patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.